Everolimus

CHEMBL1908360 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

958.2 g/mol

LogP

5.9

Phase

4

This medication works by blocking a key signaling pathway called mTOR that many cancer cells rely on to grow, and also suppresses the immune system to prevent organ rejection after transplant. It is used for both cancer treatment and transplant medicine.

Molecular Weight

958.2000 g/mol

LogP

5.90

TPSA

205.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Age-Related Macular Degeneration Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Pain Colorectal Cancer Epilepsy Hepatitis C HIV/AIDS Leukemia Lymphoma Melanoma Non-Small Cell Lung Cancer Oncology Ovarian Cancer Pain Management Pancreatic Cancer Prostate Cancer Systemic Lupus Erythematosus Thyroid Cancer Tuberculosis Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

InChI

InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

Molecular Formula

C53H83NO14

HBD / HBA

3 / 14

Rotatable Bonds

9

Heavy Atoms

68

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This medication works by blocking a key signaling pathway called mTOR that many cancer cells rely on to grow, and also suppresses the immune system to prevent organ rejection after transplant. It is used for both cancer treatment and transplant medicine.

Yes, Everolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1908360. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6442177. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Everolimus on PillFYI

Structure

Quick Data

Formula: C53H83NO14
Synonyms: 3

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.